title: First clinical trials of endostatin yield lukewarm results.
authors.forename: Renee
authors.initials: R
authors.lastname: Twombly
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003094:Collagen / Q000008:administration & dosage / Q000494:pharmacology*; D043169:Endostatins; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D003094:Collagen